Is it safe and/or necessary to combine osimertinib and carboplatin/paclixel for a patient with stage IV EGFR mutated NSCLC and advanced ovarian carcinoma?  

Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however if the NSCLC is not responding but the ovarian cancer is, combining chemotherapy with TKI is not addressed in the guidelines. 

Answer from: Medical Oncologist at Academic Institution